Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer
Authors
Keywords
Gastric cancer, CIK, MICA, Adjuvant chemotherapy
Journal
IMMUNOLOGIC RESEARCH
Volume 64, Issue 1, Pages 251-259
Publisher
Springer Nature
Online
2015-11-25
DOI
10.1007/s12026-015-8743-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- (2015) Claudia Allemani et al. LANCET
- An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells
- (2014) Clara E Jäkel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Adjuvant treatment for gastric cancer: too much is not enough
- (2014) David H Ilson LANCET ONCOLOGY
- Management of gastric cancer in Asia: resource-stratified guidelines
- (2013) Lin Shen et al. LANCET ONCOLOGY
- Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy
- (2013) Yu Chen et al. PLoS One
- Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors
- (2012) Giulia Mesiano et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase 3 Trial of Postoperative Chemotherapy Alone Versus Chemoradiation Therapy in Stage III-IV Gastric Cancer Treated With R0 Gastrectomy and D2 Lymph Node Dissection
- (2012) Tae Hyun Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity
- (2011) A. Pievani et al. BLOOD
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
- (2010) C. Hontscha et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune Therapy for Cancer
- (2008) Michael Dougan et al. Annual Review of Immunology
- Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
- (2008) Kui Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers
- (2008) Dario Sangiolo et al. INTERNATIONAL IMMUNOLOGY
- D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer
- (2008) Mitsuru Sasako et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started